Artivion, INC

Artivion, Inc. has finalized its acquisition of Endospan Ltd., a move that significantly strengthens its position in the aortic arch disease market with the addition of the NEXUS product line.

Artivion shareholders re-elected all director nominees and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Artivion announced the exercise of its option to acquire Endospan for $135 million, following FDA approval of Endospan's Nexus product, alongside reporting Q1 2026 financial results.

Artivion, Inc. announced robust financial results for Q4 and full year 2025, driven by double-digit revenue and EBITDA growth, alongside positive clinical trial data and regulatory progress.

Artivion, Inc. reported exceptionally strong third-quarter 2025 financial results, driven by robust revenue growth and significant adjusted EBITDA increase, leading to raised full-year guidance.

Artivion, Inc. is acquiring two properties in Austin, Texas for $20.5 million to secure its On-X manufacturing operations and support future expansion.

Artivion reported strong first-quarter 2026 financial results, highlighted by an 18% revenue increase and the strategic acquisition of Endospan.

Artivion, Inc. announced significant revenue growth and a substantial reduction in debt for the third quarter and first nine months of 2025, driven by strong product sales and strategic financial restructuring.

Artivion, Inc. reported a 15% increase in total revenues for Q2 2025, reaching $113 million, while significantly reducing long-term debt through strategic financial maneuvers.

Artivion's Q1 2025 results show a slight revenue increase but are impacted by a cybersecurity incident and changes in contingent consideration.

Artivion's Q3 2024 results show revenue growth driven by key product lines, offset by a net loss and increased interest expenses due to recent debt refinancing.

Artivion's Q2 2024 results show a revenue increase but a net loss, alongside strategic amendments to loan agreements.

Artivion's 2024 results show revenue growth offset by a net loss, influenced by a cybersecurity incident and strategic investments.

Artivion, Inc. has engaged former executive D. Ashley Lee as an independent consultant for a 12-month period, with a monthly fee of $41,250.

Andrew M. Green, SVP at Artivion, Inc., executed a series of stock transactions on June 11, 2026, under a pre-established Rule 10b5-1 trading plan.

Director Anthony B. Semedo transferred 6,325 shares of Artivion common stock to a living trust for estate planning purposes.

Director Marna P. Borgstrom filed an amendment to correct administrative errors regarding a restricted stock award grant date and share count.

Artivion, Inc. director Anthony B. Semedo was granted 7,576 shares of common stock as part of an equity incentive plan.

Director Jon W. Salveson was granted 7,576 shares of Artivion, Inc. common stock as part of an equity incentive plan.

Artivion, Inc. director Elizabeth A. Hoff was granted 7,576 shares of common stock as part of an equity incentive plan.

Artivion, Inc. announced its virtual 2026 Annual Meeting of Stockholders, revealing robust 2025 financial performance with 13.2% constant currency revenue growth and 28.6% adjusted EBITDA growth, alongside executive compensation details and governance updates.

Artivion, Inc. will hold its annual stockholder meeting virtually on May 13, 2025, to vote on director elections, executive compensation, auditor ratification, and an equity incentive plan.

Artivion is asking stockholders to approve additional funding for its equity incentive plan at the upcoming annual meeting on May 13, 2025.

Artivion, Inc. will hold its annual stockholders meeting virtually on May 14, 2024, to vote on director elections, executive compensation, auditor ratification, and an amendment to the certificate of incorporation.

Artivion's proxy statement outlines proposals for the upcoming annual meeting, including director elections, executive compensation, auditor ratification, and an amendment to allow officer exculpation.

Juniper Investment Company and its affiliated funds have reduced their beneficial ownership in Artivion, Inc. to 4.0% through recent share sales.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Artivion Inc. following an internal realignment.

Macquarie Group Limited and its affiliates have reported a complete divestment of their beneficial ownership in Artivion Inc, now holding 0.00% of common shares.

Perceptive Advisors and related entities have filed an amendment to their Schedule 13G, disclosing a 4.3% beneficial ownership in Artivion, Inc. common stock.

Macquarie Group Limited and its affiliates have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 5.26% in Artivion Inc. common shares.

Morgan Stanley has reduced its beneficial ownership in Artivion, Inc. to 4.4% of common stock, falling below the 5% reporting threshold.

BlackRock, Inc. filed an amended Schedule 13G, disclosing a 12.7% beneficial ownership in Artivion, Inc.'s common stock.